ClinicalTrials.gg
RecruitingNCT07932041Updated Nov 12, 2026

A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM9528

A Phase 1 interventional study of ISM9528 capsules in Healthy Subjects (HS), sponsored by InSilico Medicine Hong Kong Limited. Recruiting at 1 site in United Arab Emirates. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by InSilico Medicine Hong Kong Limited · Phase 1, Interventional, and Treatment

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This is an open-label, phase 1, sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending dose of ISM9528 in healthy adult.

02

Conditions studied

  • Healthy Subjects (HS)

Keywords

  • TNIK inhibitor
  • ISM9528
03

In context

Lead sponsor

InSilico Medicine Hong Kong Limited is the lead sponsor of 12 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The participant must meet all the following criteria to be included in the study:

  1. Male, ≥18 and ≤65 years of age.
  2. >18.5 and \<30.0 kg/m2 and body weight ≥50.0 kg for male.
  3. Non-smokers (no use of tobacco or nicotine products from 3 months prior to screening through the EOS visit).
  4. Healthy as defined the current protocol.
  5. Male participant who are not vasectomized for at least 3 months prior to dosing, and who are sexually active with a female partner of must be willing to use the acceptable methods as defined the current protocol from the first dose and for 90 days after the last dose.
  6. Male participant (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the first dose and for 90 days after the last dose.
  7. Male participant must be willing not to donate sperm for 90 days after the last dose.
  8. Able to understand the study procedures and provide signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

Participant for whom any of the following applies will be excluded from the study:

  1. The participant had current evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  2. Any clinically significant abnormal finding at physical examination.
  3. The participant had any condition possibly affecting drug absorption.
  4. Presence of fever (body temperature >37.5°C) (e.g., a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to dosing.
  5. The participant had supine blood pressure (BP) >140 mm Hg (systolic) or >90 mm Hg (diastolic) following at least 5 minutes of supine rest.
  6. The participant has HR less than 50 or over 100 bpm.
  7. The participant had 12-lead demonstrating interval by Fridericia (QTcF) >450 msec or a QRS interval >120 msec at screening.
  8. The participant had any of the abnormalities as defined the current protocol in clinical laboratory tests at screening.
  9. C-SSRS score above Type 1 ideation at Screening.
  10. Clinically significant abnormal laboratory test results or positive serology test results for , antibody, or antibody at Screening.
  11. Positive urine drug screen, urine cotinine test, or urine alcohol test.
  12. History of significant allergic reactions to any drug.
  13. History of any central nervous system (CNS) disorder or history of seizure of any cause.
  14. History of drug abuse within 1 year prior to screening or recreational use of soft drugs within 1 month or hard drugs within 3 months prior to screening.
  15. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week or who are unwilling to abstain from alcohol during the study.
  16. History of active tuberculosis or presence of active or latent tuberculosis at Screening.
  17. History of clinically significant opportunistic infection.
  18. History of serious local infection or systemic infection within 3 months prior to screening.
  19. Use of medications for the timeframes specified below, with the exception of medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or participant safety.
  20. Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
  21. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing.
  22. Participant who consumed excessive amounts of tea, coffee, or caffeine-containing beverages within 3 months prior to screening, or who are unwilling to abstain from coffee during the study.
  23. Participant who have consumed specific foods/beverages within 48 hours prior to dosing.
  24. The participant had a history of cancer with the exception of adequately treated basal cell or squamous cell carcinoma of the skin.
  25. Withdrawal of the hand before 15 seconds of immersion or after 120 seconds in the cold water bath in any cold pressor test during the Screening familiarization sessions.
  26. The Lower \< 50% of the higher PTT in the second and third CPT assessments among the three cold pressor tests performed during Screening.
  27. Participant who have difficulty in venous blood collection or have a history of needle and blood fainting.
  28. Participant with dysphagia, or who are unable to swallow the study drug whole as judged by the investigator.
  29. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1 participant (estimated)

Study arms

  • Experimental
    ISM9528 capsule will be administered orally with three single doses in a healthy male participant.

    Drug: ISM9528 capsules

Interventions

  • DrugISM9528 capsules

    ISM9528 capsules will be orally administered as per the schedule specified in the protocol.

06

What researchers measure

Primary outcomes

  1. The incidence of Adverse Events (AEs) after single dose of ISM9528 capsules.

    To evaluate the safety and tolerability of ISM9528.

    Time frame: Up to 28 days after last dose.

  2. The incidence of abnormalities in vital signs measurements, 12-lead ECG, physical examinations,CNS safety battery,C-SSRS(Columbia Suicidality Severity Rating Scale) and clinical laboratory test.

    To evaluate the safety and tolerability of ISM9528.

    Time frame: Up to 48 hours after last dose.

Secondary outcomes

  1. Maximal observed plasma concentration (Cmax).

    To characterize plasma PK of ISM9528 after each single dose.

    Time frame: From pre-dose through at least 48 hours post-dose, depending on the dose period.

  2. Time when the maximal concentration is observed (Tmax).

    To characterize plasma PK of ISM9528 after each single dose.

    Time frame: From pre-dose through at least 48 hours post-dose, depending on the dose period.

  3. Area under the concentration-time curve from time zero to the last observed concentration (AUC0-t).

    To characterize plasma PK of ISM9528 after each single dose.

    Time frame: From pre-dose through at least 48 hours post-dose, depending on the dose period.

  4. Area under the concentration-time curve from time zero to infinity (extrapolated)(AUC0-inf).

    To characterize plasma PK of ISM9528 after each single dose.

    Time frame: From pre-dose through at least 48 hours post-dose, depending on the dose period.

  5. Terminal elimination half-life(T½).

    To characterize plasma PK of ISM9528 after each single dose.

    Time frame: From pre-dose through at least 48 hours post-dose, depending on the dose period.

  6. Apparent clearance (CL/F).

    To characterize plasma PK of ISM9528 after each single dose.

    Time frame: From pre-dose through at least 48 hours post-dose, depending on the dose period.

  7. Apparent Volume of Distribution(Vz/F)

    To characterize plasma PK of ISM9528 after each single dose.

    Time frame: From pre-dose through at least 48 hours post-dose, depending on the dose period.

  8. Percentage of AUC0-inf Obtained by Extrapolation(%AUCex).

    To characterize plasma PK of ISM9528 after each single dose.

    Time frame: From pre-dose through at least 48 hours post-dose, depending on the dose period.

  9. Terminal Elimination Rate Constant(Kel)

    To characterize plasma PK of ISM9528 after each single dose.

    Time frame: From pre-dose through at least 48 hours post-dose, depending on the dose period.

07

Study locations

1 of 1 sites recruiting
  • Yas Clinic Khalifa City
    Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Dec 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 12, 2026
StartActual
Oct 29, 2026
Primary completionEst.
Dec 3, 2026
CompletionEst.
Dec 3, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07932041
Lead sponsor
InSilico Medicine Hong Kong Limited
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Oct 29, 2026
Primary completion
Dec 3, 2026 (estimated)
Completion
Dec 3, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Johnny Ju
Contact
Insilico-Clinicaltrial@insilico.ai
+86 021-50831718

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion